EGFR and non-small cell lung carcinoma: Given that the molecular characteristics [83, 84] of NSCLC (such as the prevalence of driver mutations like EGFR), TMEs [85, 57], and response to immunotherapy [86, 87] may vary significantly across different races and geographical populations, the applicability and predictive accuracy of the FRS model in non‐European and non‐American ethnic groups have not been sufficiently validated.